Stock listing

Frankfurt:2QK Scholar Rock Holding Corporation Aktie

German listing (Frankfurt) of Scholar Rock Holding Corporation · home listing NASDAQ:SRRK

Follow Scholar Rock Holding Corporation into a list and get an email when it puts out news.

Share price · FWB:2QK

€37.77 EUR +1.46 (+4.0%)

Close on Oct 27, 2026

Day range
€36.30 – €37.77 EUROct 27, 2026
Scholar Rock Holding Corporation logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:SRRK · Home$42.91 USD-0.99 (-2.3%)932,042$44.12$44.78$42.89$43.90Close on Nov 2, 2026
Frankfurt:2QK€37.77 EUR+1.46 (+4.0%)—€36.30€37.77€36.30€36.31Close on Oct 27, 2026
Ticker
Frankfurt:2QK
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Upcoming

  • Scholar Rock Holding (NASDAQ:SRRK) Q3 2026 Earnings Call

    Tue, Nov 10, 2026 · 8:00 AM ET

    Register

Replays

  • Scholar Rock Holding (NASDAQ:SRRK) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 8:00 AM ET

    Watch Transcript

  • Scholar Rock Holding (NASDAQ:SRRK) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 8:00 AM ET

    Watch Transcript

  • Scholar Rock Holding (NASDAQ:SRRK) Q4 2025 Earnings Call

    Tue, Mar 03, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026

Oct 20, 2026

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 16, 2026

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Oct 8, 2026

Scholar Rock Announces FDA Approval of ISEMBYLD (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

Sep 14, 2026

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

Sep 2, 2026

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

Aug 21, 2026

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Aug 7, 2026

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Aug 6, 2026

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

Jul 29, 2026

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

Jul 20, 2026

All Scholar Rock Holding Corporation news

Decks

Scholar Rock Holding Corporation on 6ix

Sector
Health care
Industry
Biotechnology
News releases
27 in the last 12 months · 182 in all · newest Oct 20, 2026 · oldest 2019
Calls
11 calls with a replay · 11 with a transcript · latest Aug 6, 2026
Decks
42 decks · latest Sep 14, 2026

Where Scholar Rock Holding Corporation is listed

ListingExchangeCountryCurrency
NASDAQ:SRRK · Home listingNASDAQUnited StatesUSD
Tradegate:2QKTradegateGermanyEUR
LS Exchange:A2JMQWLS ExchangeGermanyEUR
gettex:2QKgettexGermanyEUR
Lang & Schwarz:A2JMQWLang & SchwarzGermanyEUR
BOATS:SRRKBOATSUnited StatesUSD
Frankfurt:2QK · This pageFrankfurtGermanyEUR
Stuttgart:2QKStuttgartGermanyEUR
Dusseldorf:2QKDusseldorfGermanyEUR
Hamburg:2QKHamburgGermanyEUR
Munich:2QKMunichGermanyEUR

Log in to ask 6ix AI your own questions about Scholar Rock Holding Corporation.